Bio-Rad Laboratories (BIO)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$386.11-0.46%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · BIO
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $386 BIO trades at 42× p/e, in line with its 34× p/e peer median — but our blended $337 fair value sits below the price. It's a high-confidence read. Analysts target $310–$390. Even valued only for durable growth at sustainable margins, it's worth about $414 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $345.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $515.98 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $729.22 | — | — | Hist. CAGR | high |
| graham number | 12M | $236.35 | — | — | TTM | high |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$310.00 – $390.00 (median $345.00) · 4 analysts · as of 2026-08-07
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $228.54 |
| 18.0 |
| 14.11 |
| TTM |
| high |
| Peer P/FCF | 12M | $456.57 | 34.7 | 13.17 | TTM | high |
| Peer P/E | 12M | $314.63 | 33.9 | 9.28 | TTM | high |
| Peer P/S | 12M | $551.06 | 5.7 | 96.57 | TTM | high |
| residual income | 12M | $216.84 | — | — | TTM | high |
| Own P/E history | 12M | $297.18 | 32.0 | 9.28 | TTM | high |
| triangulated | 12M | $328.63 | 33.9 | 9.69 | Triangulated | high |
| Peer P/FCF | 3Y | $694.39 | 34.7 | 20.03 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $343.18 | 33.9 | 10.12 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $553.55 | 5.7 | 97.00 | guidance | medium |
| Own P/E history | 3Y | $324.15 | 32.0 | 10.12 | Hist. CAGR(prov.) | medium |
| Peer P/FCF | 5Y | $918.33 | 34.7 | 26.49 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $334.65 | 33.9 | 9.87 | Hist. CAGR(prov.) | high |
| Peer P/S | 5Y | $539.80 | 5.7 | 94.59 | guidance | high |
| Own P/E history | 5Y | $316.09 | 32.0 | 9.87 | Hist. CAGR(prov.) | high |